Jeevan Shetty News Today

Sofie Van Gijsel: Welcome all to the audio webcast of Galapagos Q1 2024 Results. Im Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

Galapagos is a latecomer to CAR T-therapy, but the drugmaker hopes its technology for producing cell therapies at a clinical site will help it stand out. Galapagos has encouraging preliminary data from two early-stage programs and it just begun Phase 1/2 testing of its third cancer cell therapy.

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility...

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed i...

Operator: Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

EPISODE-15 - COMIC RELIEF – MINDING ONE’S OWN BUSINESS!! By Donald D’ Silva, Mira Road, Karkala Donald D’ Silva is an Advertising Professional & Brand

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine... | June 5, 2023

'BALE VOTE PADLEY!' (COME CAST YOUR VOTE) St Aloysius High School, Mangaluru Art Teacher/Freelance Cartoonist JOHN CHANDRAN Creates Awareness on Voting in